Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Research & Development (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Research & Development readings, the most recent being $11.2 million for Q1 2026.

  • Quarterly Research & Development rose 67.91% to $11.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $30.1 million through Mar 2026, down 8.83% year-over-year, with the annual reading at $25.6 million for FY2025, 30.42% down from the prior year.
  • Research & Development hit $11.2 million in Q1 2026 for Ovid Therapeutics, up from $6.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $12.6 million in Q2 2024 and bottomed at $5.2 million in Q3 2022.
  • Average Research & Development over 5 years is $7.5 million, with a median of $6.6 million recorded in 2025.
  • The largest annual shift saw Research & Development crashed 54.83% in 2022 before it soared 109.73% in 2024.
  • Ovid Therapeutics' Research & Development stood at $5.6 million in 2022, then skyrocketed by 91.53% to $10.6 million in 2023, then tumbled by 44.34% to $5.9 million in 2024, then grew by 11.24% to $6.6 million in 2025, then skyrocketed by 69.69% to $11.2 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Research & Development are $11.2 million (Q1 2026), $6.6 million (Q4 2025), and $5.9 million (Q3 2025).